Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review

详细信息    查看全文

• 作者：Massimo Radin ; Savino Sciascia ; Dario Roccatello ; Maria Jose Cuadrado
• 刊名：BioDrugs
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：31
• 期：1
• 页码：37-49
• 全文大小：
• 刊物主题：Molecular Medicine; Antibodies; Cancer Research; Pharmacotherapy;
• 出版者：Springer International Publishing
• ISSN：1179-190X
• 卷排序：31

文摘

BackgroundBiological therapies represent a fundamental innovation for the management of inflammatory bowel diseases (IBD). However, many biological originators have reached, or are about to reach, patent expiry and long-term therapy costs have become progressively unsustainable. CT-P13, a biosimilar of the anti-tumor necrosis factor (anti-TNF) monoclonal antibody infliximab, might represent a significant alternative to its originator, with the potential to decrease medical care costs and, therefore, become available to a large number of patients.